Q32 Bio Inc. (NASDAQ:QTTB – Free Report) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of Q32 Bio in a report issued on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.38) per share for the year, up from their prior estimate of ($1.56). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Q32 Bio’s Q4 2026 earnings at ($0.29) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($1.27) EPS, FY2029 earnings at $0.94 EPS and FY2030 earnings at $2.36 EPS.
Q32 Bio (NASDAQ:QTTB – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.07.
Several other equities research analysts also recently weighed in on QTTB. Cantor Fitzgerald reissued an “overweight” rating on shares of Q32 Bio in a research note on Wednesday, September 16th. Mizuho raised shares of Q32 Bio to a “strong-buy” rating in a research note on Monday, September 7th. Leerink Partners assumed coverage on shares of Q32 Bio in a report on Monday, October 12th. They set an “outperform” rating and a $40.00 price target on the stock. Oppenheimer reissued an “outperform” rating on shares of Q32 Bio in a research report on Thursday, October 1st. Finally, Weiss Ratings raised shares of Q32 Bio from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, August 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.17.
Get Our Latest Stock Report on Q32 Bio
Q32 Bio Stock Down 1.3%
Shares of QTTB opened at $8.85 on Friday. The business has a fifty day moving average of $9.86 and a 200 day moving average of $9.33. The company has a market cap of $263.46 million, a PE ratio of 2.65 and a beta of 0.45. Q32 Bio has a 52-week low of $1.90 and a 52-week high of $23.57.
Insider Buying and Selling at Q32 Bio
In other news, CFO Lee Kalowski sold 3,972 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $65,776.32. Following the transaction, the chief financial officer owned 138,471 shares of the company’s stock, valued at approximately $2,293,079.76. This represents a 2.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the transaction, the insider owned 127,771 shares in the company, valued at approximately $2,115,887.76. This represents a 2.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 22,054 shares of company stock valued at $320,397 in the last ninety days. Corporate insiders own 34.46% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers purchased a new position in Q32 Bio during the 1st quarter valued at about $133,000. ADAR1 Capital Management LLC lifted its position in shares of Q32 Bio by 75.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 35,000 shares of the company’s stock worth $225,000 after purchasing an additional 15,000 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Q32 Bio in the 2nd quarter worth approximately $297,000. Squarepoint Ops LLC bought a new position in shares of Q32 Bio during the second quarter valued at approximately $303,000. Finally, Carlyle Group Inc. bought a new position in shares of Q32 Bio during the second quarter valued at approximately $769,000. 31.32% of the stock is currently owned by institutional investors.
Q32 Bio Company Profile
Q32 Bio Inc (NASDAQ: QTTB) is a clinical-stage biotechnology company focused on developing biologic therapies for diseases associated with immune-system dysfunction. The company’s research programs are designed to restore immune balance rather than broadly suppress immune activity.
Q32 Bio’s lead product candidate is bempikibart, formerly known as ADX-914, a fully human monoclonal antibody that targets activin receptor type IIA (ActRIIA). The company has evaluated bempikibart in inflammatory and autoimmune conditions, including atopic dermatitis and alopecia areata.
The company also has pursued additional immunology programs, including therapies intended to address complement-mediated disease.
Featured Stories
- Five stocks we like better than Q32 Bio
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Q32 Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q32 Bio and related companies with MarketBeat.com's FREE daily email newsletter.
